Tesaro’s niraparib has been approved as a maintenance therapy for ovarian cancer in the US, although the company experienced a setback in its bid to develop the drug in breast cancer after ...

U.S. biopharmaceutical company Tesaro is discussing its options with investment banks after receiving acquisition interest from several drug makers, according to people familiar with the matter.

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer. The alliance is important for Tesaro, which is ...